<DOC>
	<DOCNO>NCT02631473</DOCNO>
	<brief_summary>This study open-label , prospective pharmacokinetic study investigate two antiretroviral agent parallel employ adaptive design two stage , whereby result obtain primary stage inform dose select investigation secondary stage</brief_summary>
	<brief_title>PK Efavirenz &amp; Lopinavir Nano-formulations Healthy Volunteers</brief_title>
	<detailed_description>The objective study : Primary - To investigate pharmacokinetics new pharmaceutical formulation efavirenz ( NANO-efavirenz ) HIV negative healthy volunteer single dose steady-state . - To investigate pharmacokinetics new pharmaceutical formulation lopinavir ( NANO-lopinavir ) HIV negative healthy volunteer Secondary - To investigate safety tolerability NANO-efavirenz NANO-lopinavir HIV negative healthy volunteer - To assess bioequivalence select single-dose NANO-efavirenz single dose 600mg efavirenz Sustiva® - To investigate association genetic polymorphism drug disposition gene drug exposure</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Volunteers must meet follow inclusion criterion within 28 day prior baseline visit : 1 . The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement 2 . Male nonpregnant , nonlactating female 3 . Between 18 65 year , inclusive 4 . Body Mass Index ( BMI ) 18 30 kg/m2 , inclusive 5 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study period least 12 week study A female may eligible enter participate study : 1. nonchildbearing potential define either postmenopausal ( 12 month spontaneous amenorrhea ≥ 45 year age ) physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy , 2. childbearing potential negative pregnancy test Screening Day 1 agrees use one follow method contraception avoid pregnancy : Complete abstinence penilevaginal intercourse 2 week prior administration IP , throughout study , least 2 week discontinuation study medication ; Double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) ; Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year ( IUDs meet criterion , see protocol appendix 7 example listing approve IUDs ) ; Condom depot medroxyprogesterone acetate ( DMPA ) injection Male partner sterilization confirm prior female subject 's entry study , male sole partner subject ; Any method publish data show expected failure rate &lt; 1 % per year . Any contraception method must use consistently , accordance approve product label least 2 week discontinuation IP . 6 . Willing consent personal detail enter onto TOPS database 7 . Willing provide proof identity photographic ID screen subsequent visit 8 . Registered GP UK Volunteers meet follow exclusion criterion enrol study . 1 . Any significant acute chronic medical illness include hypertension ( BP persistently &gt; 140/90 mmHg ) hypotension ( BP persistently &lt; 90/60 mmHg ) 2 . Prolongation ECG interval : PR &gt; 200 msec QTcF &gt; 450 msec . 3 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination . 4 . Liver transaminase ( ALT AST &gt; 1.25 x upper limit normal range ) 5 . Significant psychiatric history ( include severe depression ) history seizure . 6 . Positive blood screen either hepatitis B surface antigen hepatitis C antibody 7 . Positive blood screen HIV1 and/or 2 antibody 8 . Current recent ( within 3 month ) gastrointestinal disease 9 . Clinically relevant alcohol drug use ( positive urine drug screen ) history alcohol drug use consider Investigator sufficient hinder adherence treatment , followup procedure evaluation adverse event . Smoking permit , tobacco intake remain consistent throughout study 10 . Known cardiac disease history family history sudden cardiac death . 11 . Exposure investigational drug placebo within 3 month first dose study drug 12 . Use drug ( unless approve Investigator ) , include overthecounter medication herbal preparation , within two week prior first dose study drug , unless approved/prescribed Principal Investigator know interact study drug . 13 . Females childbearing potential without use effective nonhormonal birth control method , willing continue practise birth control method least 12 week end treatment period 14 . Previous allergy constituent pharmaceutical administer trial 15 . Rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>